ClinicalTrials.gg
CompletedNCT07650383Updated Jun 16, 2026

A Study to Evaluate ENERGI-F705 Tablets in Healthy Volunteers

A Phase 1 interventional study of ENERGI-F705 Tablets 60 mg and ENERGI-F705 Tablets 120 mg in Health Adult Subjects, sponsored by Energenesis Biomedical Co., Ltd.. Completed at 1 site in Taiwan. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Energenesis Biomedical Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Feb 2025, registered May 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

To evaluate the safety, the tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of ENERGI-F705 Tablets in healthy subjects.

02

Conditions studied

  • Health Adult Subjects
03

In context

Lead sponsor

Energenesis Biomedical Co., Ltd. is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All genders aged ≧18 to \< 45 years.
  2. Able to understand and sign form.
  3. Able to communicate well with the Investigator and comply with the requirements of the study.
  4. (BMI) ranged 18.5≦BMI \< 27 kg/m2 .
  5. Males weighting ≧50 kg and females weighting ≧45 kg.
  6. Healthy subjects as determined by a responsible physician, based on medical evaluation including medical history, physical examination, concomitant medication, vital signs, 12-lead , chest X-ray, and clinical laboratory evaluations.
  7. Is willing to follow the study life style instruction and protocol procedure
  8. Negative test for (HIV), syphilis, virus surface antigen (HBsAg), and anti- antibody at screening.

    -

Exclusion criteria

Exclusion Criteria:

  1. History of adverse reactions or allergy of active ingredient, components in IP or related products.
  2. Significant drug abuse.
  3. Having any medical history as judged by the Investigator (including but not limited to neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorders).
  4. Presence of significant neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, renal, or other pathology, as judged by the Investigator.
  5. Pregnant or lactating women.
  6. Having an acute illness or surgery within 4 weeks prior to dosing.
  7. Other conditions not suitable for participating in this study as judged by the Investigator.
  8. History of cancer () or have ever received any anti-cancer therapy.
  9. Taking any prescription, vaccine, herbal products or over-the-counter (OTC) medication, including antacids, calcium, other supplements and vitamins, that may interfere with the safety or PK/PD assessment judged by the Investigator within 14 days prior to dosing.
  10. Joining any drug clinical trial within 2 months prior to dosing.
  11. Blood loss/donation of ≧250 mL within 2 months or blood loss/donation of ≧500 mL within 3 months prior to dosing.
  12. Healthy adult subjects or subjects' active sexual partners disagree to use at least one form of highly effective methods during the study period and for 5 half-lives of active ingredient plus 90 days (94 days in total) after dosing. During this time, sperm or egg donation is prohibited while contraceptive methods are in use.

    • Acceptable forms of highly effective contraceptive methods for female subjects include:

      • Surgically sterile (documented hysterectomy, documented bilateral salpingectomy, bilateral oophorectomy)
      • Placement of an intrauterine device (IUD) in conjunction with a barrier method (use of condom by the male partner)
      • Total sexual abstinence
    • Acceptable forms of highly effective contraceptive methods for male subjects include:

      • Surgically sterile (vasectomy with documented negative semen analysis)
      • Condom in conjunction with an IUD (used by the female partner)
      • Condom in conjunction with oral/implantable/injectable contraceptives (used by the female partner)
      • Total sexual abstinence
  13. Having a rare hereditary problem of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
  14. The result of or ALT >2 times the or presence of abnormality, as judged by the Investigator.
  15. The result of creatinine is abnormal or \< 90 mL/min/1.73 m2 or presence of clinically significant abnormality, as judged by the Investigator.
  16. Presence of, history of, or suspected gout, hyperuricemia or urolithiasis, as judged by the Investigator.
  17. Clinically significant abnormality at screening.
  18. Presence of risk for , as judged by the Investigator.
  19. Regular smoker.

    • Regular smoker is defined as who smokes every day (≥ 1 cigarette/day in average in the past 8 weeks of Screening)
  20. Consumed greater than 3 units of alcoholic beverages per day in average for the past 4 weeks prior to dosing.

    • One unit is equivalent to one can of beer (\<10% alcohol; about 330 mL), one glass of wine (10\~20% alcohol; about 150 mL), or one shot of distilled spirits (>20% alcohol; about 45 mL)
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    ENERGI-F705 60 mg

    Drug: ENERGI-F705 Tablets 60 mg

  • Active comparator
    ENERGI-F705 120 mg

    Drug: ENERGI-F705 Tablets 120 mg

  • Placebo comparator
    Vehicle Control

    Drug: Vehicle Control

Interventions

  • DrugENERGI-F705 Tablets 60 mg

    ENERGI-F705 tablets administered orally under fasting conditions.

  • DrugENERGI-F705 Tablets 120 mg

    ENERGI-F705 tablets administered orally under fasting conditions.

  • DrugVehicle Control

    Matched vehicle control tablets administered orally under fasting conditions.

06

What researchers measure

Primary outcomes

  1. Number and Percentage of Subjects with Treatment-Emergent Adverse Events (TEAEs)

    Number and percentage of subjects with treatment-emergent adverse events (TEAEs).

    Time frame: From dosing through end of study (approximately 4 days post-dose)

Secondary outcomes

  1. Maximum Observed Whole Blood Concentration (Cmax) of ENERGI-F705 and Its Metabolite Following Single Oral Administration

    Cmax is defined as the highest observed whole blood concentration within the 72-hour sampling period. Values will be reported separately for ENERGI-F705 and its metabolite in ng/mL.

    Time frame: From pre-dose to 72 hours post-dose

  2. Time to Maximum Observed Whole Blood Concentration (Tmax) of ENERGI-F705 and Its Metabolite Following Single Oral Administration

    Tmax is defined as the time point at which Cmax is observed within the 72-hour sampling period. Values will be reported separately for ENERGI-F705 and its metabolite in hours.

    Time frame: From pre-dose to 72 hours post-dose

  3. Trough Whole Blood Concentration (Ctrough) of ENERGI-F705 and Its Metabolite at 72 Hours Following Single Oral Administration

    Ctrough is defined as the whole blood concentration measured at 72 hours post-dose. Values will be reported separately for ENERGI-F705 and its metabolite in ng/mL.

    Time frame: From pre-dose to 72 hours post-dose

  4. Area Under the Whole Blood Concentration-Time Curve (AUC) of ENERGI-F705 and Its Metabolite Following Single Oral Administration

    AUC0-t is defined as the area under the concentration-time curve from time zero to the last measurable concentration time point. AUC0-∞ is defined as the area under the concentration-time curve from time zero to infinity. Both values will be reported separately for ENERGI-F705 and its metabolite in ng·h/mL.

    Time frame: From pre-dose to 72 hours post-dose

  5. Terminal Elimination Half-life (T½) of ENERGI-F705 and Its Metabolite Following Single Oral Administration

    T½ is defined as the terminal half-life, calculated as ln(2) / K\_el ≈ 0.693 / K\_el. Values will be reported separately for ENERGI-F705 and its metabolite in hours.

    Time frame: From pre-dose to 72 hours post-dose

  6. Apparent Total Body Clearance (CL/F) of ENERGI-F705 and Its Metabolite Following Single Oral Administration

    CL/F is defined as the apparent total body clearance, calculated as Dose / AUC0-∞. Values will be reported separately for ENERGI-F705 and its metabolite in L/h.

    Time frame: From pre-dose to 72 hours post-dose

  7. Apparent Volume of Distribution (Vd/F) of ENERGI-F705 and Its Metabolite Following Single Oral Administration

    Vd/F is defined as the apparent volume of distribution, calculated as Dose / (K\_el × AUC0-∞). Values will be reported separately for ENERGI-F705 and its metabolite in liters (L).

    Time frame: From pre-dose to 72 hours post-dose

  8. Whole Blood Adenosine Triphosphate (ATP) Level Following Single Oral Administration of ENERGI-F705 Tablets

    ATP levels will be measured in whole blood at each scheduled time point within the 72-hour sampling period.

    Time frame: From pre-dose to 72 hours post-dose

07

Study locations

1 site
  • Taipei Medical University Hospital
    Taipei, Taiwan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in May 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2026
First posted
Jun 16, 2026
StartActual
Feb 24, 2025
Primary completionActual
May 6, 2025
CompletionActual
Nov 19, 2025
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07650383
Responsible party
Sponsor
First posted
Jun 16, 2026
Start date
Feb 24, 2025
Primary completion
May 6, 2025
Completion
Nov 19, 2025
Last update
Jun 16, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion